Your search
Results 415 resources
-
Respiratory viruses have been recognized as a significant cause of morbidity and mortality in patients with leukemia and those undergoing hematopoietic stem cell transplantation. The risk for lower respiratory tract infections and a fatal outcome appears to depend on the intrinsic virulence of the specific community-acquired respiratory virus as well as factors specific to the patient, the underlying disease, and its treatment., Community-acquired respiratory virus (CARV) infections have...
-
Human adenovirus (HAdV) infections are increasingly recognized as important pathogens in immunocompromised hosts, especially in patients with severely suppressed T-cell function. The 4th European Conference of Infections in Leukemia (ECIL-4) has developed evidence-based guidelines for diagnosis and management of HAdV infections. The risk for HAdV-associated disease is increased in children, and risk factors for HAdV disease are T-cell depletion, unrelated and cord blood hematopoietic stem...
-
Purpose To evaluate the risk factors for cytomegalovirus (CMV) retinitis in patients with CMV viremia after hematopoietic stem cell transplantation (HSCT). Design Retrospective cohort study. Participants We included all patients with CMV viremia detected by polymerase chain reaction after HSCT between April 2009 and August 2011. Risk factors for CMV retinitis were evaluated in the cohort of 270 patients with CMV viremia, who survived ≥12 weeks after HSCT and were screened for CMV...
-
Summary: The number of patients with acquired immunodeficiency has grown steadily as a result of both a larger number of patients receiving solid organ and hematopoietic stem cell transplants and their longer survival times. The use of newer, more potent immunosuppressive regimens has increased the frequency of severe adenovirus infections. Human adenoviruses are a large group of viruses, represented by at least 52 serotypes with various genotypes divided into genomic clusters, and these may...
-
International travel is associated with an increased risk of enteric, vector-borne and bloodborne infections. The risk of acquiring travel-related illness is higher in those who are immunocompromised. However, little is known about travel practices and risk behaviors in transplant recipients who travel. We herein profile transplant recipients who travel, and characterize their pretravel precautions, travel activities, burden of illness, and exposure history.With the use of a standardized and...
-
Shared with Dropbox
-
Learn about measles disease course and what to do if you have a suspected case.
-
Introduction Cytomegalovirus (CMV) causes significant morbidity in solid organ transplant recipients (SOTR). Measuring cell-mediated immunity (CMI) may inform the risk of CMV infection after antiviral prophylaxis and predict relapse after CMV treatment. Methods We serially assessed CMV CMI using the QuantiFERON-CMV assay (QF-CMV; Qiagen, Germantown, MD) in two cohorts of SOTRs: during valganciclovir prophylaxis and during treatment of CMV viremia. Results of CMI were correlated with...
-
Background The frequency and significance of cytomegalovirus (CMV) infection in seropositive (R+) heart transplant recipients (HTR) is unclear, with preventative recommendations mostly extrapolated from other groups. We evaluated the incidence and severity of CMV infection in R+ HTR, to identify risk factors and describe outcomes. Methods R+ HTR from 2010 to 2019 were included. Antiviral prophylaxis was not routinely used, with clinically guided monitoring the local standard of care. The...
-
Introduction: Letermovir is a cytomegalovirus (CMV) terminase complex inhibitor approved for prophylaxis of CMV infection and disease in adult CMV-seropositive allogeneic hematopoietic cell transplantation (allo-HCT) recipients (R+). We report pharmacokinetics (PK), safety, and efficacy of letermovir in adolescent (12–18 years) allogeneic HCT recipients from an ongoing clinical study. Methods: In this phase 2b, multicenter, open-label study (NCT03940586), 28...
-
IDSA Guidelines on Antigen Testing for the Diagnosis of COVID-19 now available. These evidence-based rapid guidelines will address pressing clinical questions related to optimal use of SARS-CoV-2 Antigen tests in both medical and non-medical settings.
Filter by our tag
GUIDELINES
- AASLD Guidelines (2)
- AST Guidelines 2019 (13)
- ASTCT Guidelines (7)
- ECIL Guidelines (8)
- ESCMID Guidelines (3)
- IDSA Guidelines (8)
- TTS Guidelines (1)
TEXTBOOKS
CORE CURRICULUM
ORGANISMS
-
VIRUSES
- Adenovirus (17)
- Arboviruses (7)
-
CMV
(121)
- Cell-Mediated Immunity Assays (11)
- Clinical (55)
- Cytotoxic T-Lymphocytes (1)
- Epidemiology and Risk Factors (15)
- Letermovir (26)
- Maribavir (17)
- Preemptive Therapy (7)
-
COVID-19
(45)
- Diagnosis (3)
- Fungal superinfection (2)
- GUIDELINES (9)
- Infection Prevention (3)
- Positive Donors (6)
- Positive Recipients (5)
- Treatments (18)
- Vaccination (8)
- Hepatitis A (2)
- Hepatitis B (27)
- Hepatitis C (31)
- Hepatitis D (5)
- Hepatitis E (5)
- HHV-6 (24)
- HHV-8 (4)
- HIV (31)
- HPV (5)
- HSV (4)
- Influenza (17)
- Measles (22)
- Mpox (6)
- Norovirus (8)
- Parvovirus B19 (3)
- Polyomaviruses (32)
- Respiratory Viruses (32)
- RSV (18)
- VZV (17)
- WNV (2)
-
BACTERIA
(1)
- C. difficile (1)
-
FUNGI
(2)
- Aspergillus (2)
- Candida (1)
- Mucormycosis (1)
- Rarer Fungi (1)
DRUGS AND THERAPIES
- Antibiotics (1)
- Antifungals (1)
- Antivirals (8)
- Cytotoxic T-lymphocyte therapy (4)
- Fecal Microbiota Transplantation (1)
- Stewardship (2)
PREVENTION
- Safe Living (1)
- Travel (2)
- Vaccination (27)
SYNDROMES AND CONDITIONS
- Diarrhea (5)
SOLID ORGANS AND MCSS
HEME-ONC AND CELLULAR THERAPIES
- Biologics (8)
- BMT Basics (1)
- BMT Guidelines (8)
- BMT-specific ID (35)
- CAR-T (4)
- Heme-onc prophylaxis (3)
- Neutropenia (1)
- PEDIATRIC (9)
- PTLD (4)
- TK inhibitors (1)
PATIENT EDUCATION
- COVID-19 (1)
- Selected Infections (1)
ATC 2024 Top Papers in TID
- VIRUSES (7)